| abstract |
REFERS TO COMPOUNDS DERIVED FROM 1,1,1-TRIFLUOR-2-HYDROXY-3-PHENYLPROPANE OF FORMULA (I) WHERE A IS C-R1b O N; R1a, R1b, R1c, R1d AND R1e ARE EACH H, ALKYL (C1-C7), CYCLOALKYL (C3-C7) -ALKYL (C1-C7), HALOGEN, HYDROXY, AMONG OTHERS; R2 IS ALKYL (C1-C7), CYCLOALKYL (C3-C7) -ALKYL (C1-C7), CARBOXYL-ALKYL (C1-C7), AMONG OTHERS; R3 IS HO (C1-C7) ALKYL; R4 IS PYRIDYL, PYRAZINYL, PYRIMIDINYL, AMONG OTHERS; R5 IS H O METHYL; n IS 0 O 1. PREFERRED COMPOUNDS ARE: 3- (2-CHLORO-4-METOXY-PHENYL) -1,1,1-TRIFLUOR-2- (5-METHYL-PIRAZIN-2-IL) -BUTAN-2- OL, 1,1,1-TRIFLUOR-2- (2-METHYL-PYRIDIN-4-IL) -3-PHENYL-BUTAN-2-OL, 3- (2,4-DICHLORO-PHENYL) -1,1, 1-TRIFLUOR-2-PYRIDIN-3-IL-BUTAN-2-OL, AMONG OTHERS. IT ALSO REFERS TO A PREPARATION PROCEDURE AND A PHARMACEUTICAL COMPOSITION. SUCH COMPOUNDS ARE ANTAGONISTS OF THE GLUCOCORTICOID RECEPTOR BEING USEFUL IN THE TREATMENT OF DIABETES |